Taiwan Advance Bio Pharmaceutical Inc. | Date: 2016-02-01
Stem cells for medical purposes; Medicines for human purposes, namely, medicines for the treatment of blood diseases such as leukemia, thalassemia and bone marrow failure; Medicinal agent for human use, namely, medicines for the treatment of blood diseases such as leukemia, thalassemia and bone marrow failure; Drug for medical use, namely, medicines for the treatment of blood diseases such as leukemia, thalassemia and bone marrow failure; Medicine for the treatment of blood diseases such as leukemia, thalassemia and bone marrow failure; Biological preparations for medical purposes in the nature of preparations for the treatment of blood diseases such as leukemia, thalassemia and bone marrow failure; Blood for medical purposes, namely, Haematogen, Blood plasma, Haemoglobin; Sero therapeutic medicines for the treatment of blood diseases such as leukemia, thalassemia and bone marrow failure. Retailing and wholesaling of drugs, namely, on-line wholesale and retail store services featuring drugs. Medical treatment services, namely, blood therapy services; Blood bank service, Blood bank services, Cord blood bank.
Sheu S.-Y.,China Medical University at Taichung |
Sheu S.-Y.,Chung Shan Medical University |
Wang Y.-K.,National Taiwan University |
Tai Y.-T.,Taiwan Advance Bio Pharmaceutical Inc. |
And 4 more authors.
Journal of Immunoassay and Immunochemistry | Year: 2013
Florfenicol (FF) is a synthetic antibiotic with a broad antibacterial spectrum and the high therapeutic effectiveness that has been developed specifically for veterinary use. Obviously, FF adulterated in animal supplies is one of essential global concerns. A competitive ELISA for the detection of florfenicol in food of animal origin (swine, chicken, and fish) is described. Influence of immunoconjugate structure on the assay sensitivity and specificity was investigated. The new ELISA showed much lower than the MRPLs for FF at 100-3,000 mg kg-1 in the European Communities and the sensitivity of our ELISA method was superior to that described in other reports. According to the test preparation record, the limit of detection of the developed ELISA performed on meat species was 0.3 μg kg-1 (IC50 value 1.9 μg kg-1). The method developed permits FF concentrations to be determined in the range 0.3-24.3 μg kg-1. A low cross-reactivity with florfenicol amine (FFA), thiamphenicol (TAP), and chloramphenicol (CAP) was displayed (16.2%, 9.5%, and 9.4%, respectively). Recovery in different food samples (swine, chicken, and fish) averages between 87-115%. The method can be applied for inspection of animal supplies for trace florfenicol residues. Copyright © Taylor & Francis Group, LLC. Source
Hsieh K.H.,Taiwan Advance Bio Pharmaceutical Inc. |
Lin C.P.,Taiwan Advance Bio Pharmaceutical Inc. |
Cheng C.C.,Taiwan Advance Bio Pharmaceutical Inc. |
Lai C.P.,Taiwan Advance Bio Pharmaceutical Inc. |
And 8 more authors.
Food Biotechnology | Year: 2013
The technology developed from this study is based on an immunochromatographic procedure that utilizes antigen-antibody properties using membrane carriers with immobilized immunoreactants and provides rapid and out-of-laboratory techniques. An evaluation of a colloidal gold-based immunochromatographic assay for chloramphenicol (CAP) residue detection in serum, milk and feed is described. Polyclonal antibodies against CAP were produced using CAP-IPA-MAA-ABA-bovine serum albumin (CAP-ed-BSA) conjugate as the immunogen, which exhibited no cross-reactivities with applied competitors in the studied concentration range. The test strip assay could be completed within 7 min, with a visual detection limit of 0.3 μg kg-1 CAP in serum and milk and 0.5 μg kg-1 CAP in feed. The established strip assay performed similarly as a commercial ELISA assay: the CAP test strip revealed a sensitivity of 90% (89-92%) and a specificity of 94% (91-98%), which showed appreciable accuracy and precision. The described strip is rapid, simple and cost-effective as well as sensitive and specific enough for reliable and accurate on-site screening. © 2013 Copyright Taylor and Francis Group, LLC. Source